Overview

Augment Biologics, a platform-enabled therapeutics company, is unlocking new possibilities in drug surface design using our landmark discovery in glycoengineering, which we call GlycoTemplating. Led by technological founders and experienced entrepreneurs, we are creating a new class of GlycoTemplated biologics.

The problem is that glycans matter, but glycoengineering is hard. By genetically encoding the desired glycosylation, we turn the challenge and risk of glycoengineering into a design opportunity. 

Starting with the $16B IVIG market, we are poised to tame the most capricious Critical Quality Attribute in biologics, transform drug development risk, and fundamentally Augment Biologics.